Sadigh Yasmin, Haasdijk Eva Joëlle, Dammers Ruben, Volovici Victor
Department of Neurosurgery, Erasmus MC Stroke Center, Erasmus MC University Medical Center, 3015 GD Rotterdam, The Netherlands.
Center for Complex Microvascular Surgery, Erasmus MC University Medical Centre, 3015 GD Rotterdam, The Netherlands.
J Clin Med. 2025 Aug 26;14(17):6027. doi: 10.3390/jcm14176027.
: Endovascular treatment has become the primary treatment for intracranial aneurysms, yet direct bypass surgery remains an option in selected cases where standard approaches fail. This study aims to evaluate the role, indications, and outcomes of bypass surgery for intracranial aneurysm management in the current endovascular era. : A single-center retrospective analysis was conducted on consecutive cases who underwent direct intracranial bypass surgery for intracranial aneurysms between 2015 and 2024. Data on demographics, aneurysm characteristics, indications, bypass type, patency, and clinical outcomes (using the modified Rankin Scale) were collected. : Of the 101 bypasses performed between 2015 and 2025, 25 were used for complex aneurysm cases. Intracranial bypass was necessary in as many as 5% of all microsurgical aneurysm repairs in 2023 and 10% in 2024. Bypass surgery was indicated in young patients with complex aneurysms not amenable to endovascular therapy (45%) and in 20% of the cases for recanalized aneurysms after previous endovascular repair. Intraoperative and postoperative bypass patency was confirmed for all patients except one case due to ongoing malignant brain swelling after an ongoing infarction. At follow-up, 87% of patients, with both ruptured and unruptured aneurysms, had a good outcome (mRS ≤ 2), and all patients had a patent bypass. Permanent morbidity was observed in 5% and procedure-related mortality in 0%. : While bypass surgery constitutes a minority of intracranial aneurysm treatment by volume, its role in intracranial aneurysm repair is crucial and relevant in response to the evolving complexity of aneurysms. Further refinement of techniques is necessary.
血管内治疗已成为颅内动脉瘤的主要治疗方法,但在某些标准方法失败的特定病例中,直接搭桥手术仍是一种选择。本研究旨在评估在当前血管内治疗时代,搭桥手术在颅内动脉瘤治疗中的作用、适应证及疗效。
对2015年至2024年间连续接受颅内动脉瘤直接搭桥手术的病例进行了单中心回顾性分析。收集了人口统计学数据、动脉瘤特征、适应证、搭桥类型、通畅情况及临床疗效(采用改良Rankin量表)。
在2015年至2025年期间进行的101例搭桥手术中,25例用于复杂动脉瘤病例。2023年,在所有显微手术治疗的动脉瘤中,高达5%需要进行颅内搭桥,2024年这一比例为10%。搭桥手术适用于不适合血管内治疗的年轻复杂动脉瘤患者(45%)以及20%既往血管内修复后再通的动脉瘤病例。除1例因持续性梗死导致恶性脑肿胀而未确认外,所有患者术中及术后搭桥均通畅。随访时,87%的动脉瘤破裂和未破裂患者预后良好(改良Rankin量表评分≤2),且所有患者的搭桥均通畅。观察到5%的患者出现永久性致残,无手术相关死亡。
虽然从手术量来看,搭桥手术在颅内动脉瘤治疗中占少数,但其在颅内动脉瘤修复中的作用至关重要,且与动脉瘤日益复杂的情况相关。有必要进一步改进技术。